---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331594"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2026-08-04T12:05:06+00:00"
generated_at: "2026-08-04T12:10:31.669723+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics appoints Michelle Gilson to Board of Directors, as Audit Committee chair

## Summary
- Michelle Gilson appointed to Board effective August 1, 2026; also named chair of Audit Committee.
- Gilson, 34, was CFO of Arcellx until its acquisition by Gilead in April 2026.
- Prior roles include Senior Biotechnology Equity Research Analyst at Canaccord Genuity (Managing Director) and earlier at Jefferies, Nomura, Oppenheimer, Goldman Sachs.
- She will receive compensation per company's Non-Employee Director Compensation Policy; standard indemnification agreement.
- No arrangements, family relationships, or material interests in transactions.

## SEC filing metadata
- accession: 0001193125-26-331594
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2026-08-04T12:05:06+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312526331594/0001193125-26-331594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312526331594/d177572d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331594
- JSON: https://secwatch.observer/filing/0001193125-26-331594.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.